Search

Displaying results 4471 - 4480 of 10000 in total
  1. Drug

    Cefprozil

    go.drugbank.com/drugs/DB01150
    ApprovedInvestigational

    Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.

  2. Drug

    VB2-011

    go.drugbank.com/drugs/DB05411
    Experimental

    VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.

  3. Drug

    Mupirocin

    go.drugbank.com/drugs/DB00410
    ApprovedInvestigationalVet approved

    [L10580] It is available in topical formulations only due to extensive systemic metabolism[A178531] and is used in the treatment of impetigo caused by _Staphylococcus aureus_ and _Streptococcus pyogenes … There is also some clinical evidence that suggests the potential role of mupirocin in eradicating nasal carriage of Staphylococci when administered intranasally.

    Synonyms: 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3- [(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl] oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
  4. Drug

    ORG-34517

    go.drugbank.com/drugs/DB05423
    Investigational

    It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high.

  5. Drug

    Cardarine

    go.drugbank.com/drugs/DB05416
    Investigational

    Cardarine (GW-501516) is a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia. Cardarine has been investigated for the treatment of Obesity, Lipid Disorders, and Cardiovascular Disease.

  6. Drug

    Danvatirsen

    go.drugbank.com/drugs/DB14825
    Investigational

    Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).

  7. Drug

    DNB-001

    go.drugbank.com/drugs/DB05757
    Investigational

    In preclinical animal models, DNB-001 has demonstrated potent IOP- lowering effects as well as neuroprotective effects on the optic nerve. … DNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed for the treatment of glaucoma.

  8. Drug

    AT-301

    go.drugbank.com/drugs/DB16507
    Investigational

    AT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine

  9. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

  10. Drug

    Veru-111

    go.drugbank.com/drugs/DB16462
    Investigational

    in adults, and metastatic triple-negative breast cancer. … VERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360.